Background: The effect of lixisenatide-a prandial once-daily glucagon-like peptide-1 recep-
normoglycaemia and an insulin regimen must be initiated. Guidelines from the American Diabetes Association/European Association for the Study of Diabetes recommend that insulin therapy begins with once-daily injection of a long-acting basal insulin, such as insulin glargine, to regulate FPG levels. [9] [10] [11] [12] GLP-1 RAs mimic the activity of GLP-1 while being resistant to degradation by DPP-4, leading to prolonged activity compared with endogenous GLP-1. Prandial (or short-acting) and long-acting GLP-1
RAs have been defined based on their pharmacokinetic, pharmacodynamic, and mechanistic differences. While prandial GLP-1 RAs exert glycaemic benefits through their effects on both slowing of gastric emptying and the incretin pathway, it is the former that has a profound impact on PPG. 13 Long-acting GLP-1 RAs exert their glycaemic effects primarily through stimulation of insulin secretion and reduction in glucagon levels and, as such, have a dominant effect on FPG. 13 The stimulation of insulin release from pancreatic β cells and reduction of glucagon levels brought about by GLP-1 RAs are both glucose dependent. 14 Currently, it remains unclear whether the degree of loss of β-cell function affects the efficacy of these agents. The present analysis was designed to investigate the influence of residual β cell function on the efficacy of a prandial GLP-1 RA and, to our knowledge, is the first of its kind on an agent of this class.
Lixisenatide (Lyxumia . [15] [16] [17] [18] [19] [20] In other studies, lixisenatide brought about significantly greater improvements in PPG than liraglutide, a long-acting GLP-1 RA, but showed more limited effects on FPG. 21, 22 Nevertheless, significant improvements in FPG were seen in the GetGoal trials in which lixisenatide was used as monotherapy or added to existing OAD treatment. 15, 16, 23, 24 Pharmacological studies have demonstrated that, although lixisenatide acts through multiple mechanisms, the marked reduction in PPG excursions associated with lixisenatide is largely caused by slowing of gastric emptying. 25 Furthermore, in vivo preclinical studies have shown that the extent of inhibition of gastric emptying with lixisenatide is so great that the reduction in PPG concentrations is associated with a reduction rather than an increase in plasma insulin. 26 This indicates that lixisenatide acts through a pathway independent of islet function, resulting in a marked alleviation of the prandial β-cell secretory burden. 27 The weight of evidence in the trials described above suggests that lixisenatide should be efficacious even in patients with markedly reduced residual β-cell function.
The homeostasis model assessment of β-cell function (HOMA-β) 28 is a widely used clinical and epidemiological tool for the assessment of β-cell function using FPG and insulin (or C-peptide) concentrations, with a higher HOMA-β index value representing better β-cell function.
The HOMA-β has been validated against several other more sophisticated methods for the assessment of β-cell function, including the hyperglycaemic clamp, the acute insulin response (following an intravenous glucose tolerance test), and the continuous infusion glucose model assessment. [28] [29] [30] [31] [32] To investigate the hypothesis that residual β-cell function is not a major determinant of the efficacy of lixisenatide, this post hoc analysis evaluated the efficacy (and safety) of lixisenatide according to patients' baseline β-cell function, as determined by HOMA-β index, using pooled data from 3 studies in the GetGoal clinical trial programme.
| SUBJECTS AND METHODS

| Study design
This was a descriptive, post hoc analysis of individual patient data extracted from the intent-to-treat populations of 3 randomized, dou- 
| Endpoints assessed
| Statistical analysis
A multivariable logistic regression model was used to assess the main variables affecting the probability of patients having high versus low HOMA-β index scores. The high versus low HOMA-β index status was the dependent variable, and age, sex, baseline BMI, duration of diabetes, baseline HbA 1c , baseline FPG, and sulphonylurea usage status were the independent variables. The propensity scores, evaluated as the probabilities from the logistic regression model, were then matched between patients with high versus low HOMA-β index scores, resulting in a population matched for the independent variables. Thereafter, study endpoints were assessed with these matched study cohorts. Additionally, the same analyses of study endpoints were also performed on the original, unmatched cohort.
In the unmatched cohort, the multivariable logistic regression analysis was also used to determine independent predictors of baseline HOMA-β scores. Furthermore, a Pearson correlation analysis was performed on the unmatched population to assess HOMA-β index at baseline versus clinical and demographic features.
Baseline demographics, clinical characteristics, and efficacy and safety outcomes were evaluated according to HOMA-β index cohort.
Outcomes for HOMA-β index cohorts were compared with one another, with P values calculated using a chi-square test for categorical variables or analysis of variance for continuous variables. Paired t tests were used to compare baseline and endpoint continuous measurements among patients within each cohort, with a P value of .05 used to determine the level of statistical significance.
3 | RESULTS
| Baseline characteristics
Of the 980 patients with T2DM treated with lixisenatide in the 3
GetGoal clinical trials who met the inclusion criteria, a total of 546 patients were included in the propensity score-matched population, 273 in each cohort (please refer to the Statistical analysis section for details on how the propensity score matching was done). Baseline characteristics were comparable across the high versus low HOMA-β index cohorts, with the exception of PPG and glucose excursion, which
were not matched in the analysis and were thus higher in the low versus high HOMA-β index cohort (Table 1) . Baseline characteristics of the unmatched cohort are shown in Table S1 .
A multivariate regression analysis of the unmatched data identified both BMI and duration of diabetes as independent predictors of HOMA-β index category at baseline (Table 2 ). FPG and HbA 1c at baseline were also identified as predictors of HOMA-β values, although this was to be expected as FPG is involved in the calculation of HOMA-β and contributes to overall HbA 1c levels. Interestingly, while the use of a sulphonylurea was not found to be a predictor of baseline HOMA-β index cohort, the P value showed a trend towards significance. Efficacy endpoints for the unmatched cohorts are shown in Table S2 .
| Pearson correlation analysis
The Pearson correlation analysis of the unmatched cohort showed that HOMA-β index at baseline correlated strongly with change in HOMA-β index over the treatment period (Table S3) . HOMA-β index at baseline also showed a strong negative correlation with age, and a moderate positive correlation with HOMA-β index at study end.
| Safety endpoints
An equal proportion of patients in the high versus low HOMA-β index cohorts experienced symptomatic hypoglycaemia (5.49% vs 5.13%, respectively; P = .8487). There were no events of severe hypoglycaemia reported in either study cohort.
| Composite endpoints
There were no statistically significant differences between the study cohorts in achieving the composite endpoints of HbA 1c < 7% with no symptomatic hypoglycaemia, HbA 1c < 7% with no weight gain and HbA 1c < 7% with no weight gain and no symptomatic hypoglycaemia (Table 3) . Composite endpoints for the unmatched population are shown in Table S4 . Bolded values reached statistical significance (P < .05).
*P value derived from maximum likelihood estimates. For instance, obese patients are characterized by more severe insulin resistance 33 and, as a result, their critical β-cell function threshold to develop diabetes is higher than that of nonobese patients. 34 Furthermore, β-cell mass has been shown to gradually decline with age in both diabetic and nondiabetic individuals, thereby accounting, at least in part, for the well-established role of age as a risk factor of T2DM. 7 Additionally, the same study showed that β-cell mass also declines with diabetes duration. 7 Other studies have shown that the functional impairment of β-cells often significantly exceeds the deficit in β-cell mass, as the secretory burden for the remaining β-cells is increased by 100% if their overall mass is reduced by just 50%. [35] [36] [37] Recent studies indicate that propensity score matching is an effective tool for comparing treatment regimens in those with diabetes and can decrease treatment selection bias between groups. 38, 39 The use of the propensity score-matching technique was a major strength of this analysis because there were several differences in baseline characteristics between patients in the high and low HOMA-β index cohorts that may have influenced the effect of lixisenatide treatment. By using propensity score matching, we were able to reduce the bias caused by shown that the delay of gastric emptying brought about by exogenous GLP-1 limits the rate and extent of PPG presented to β cells, leading to "β-cell rest" and the partial recovery of β cells and the endogenous insulin response. This effect is also evident when incretin therapies are combined with basal insulin. 40 In this scenario, the presence of exogenous insulin supplements endogenous insulin production, promoting β-cell rest. Improvements in HOMA-β index scores have also been seen with other GLP-1 RAs, 41, 42 DPP-4 inhibitors, 43 and some meglitinides. 44 In the UK Prospective Diabetes Study, an increase in β-cell function was seen at 1 year in patients receiving sulphonylureas, although this increase was not maintained over subsequent years. 45 Baseline HOMA-β levels in the present study were comparable with those seen in UK Prospective Diabetes Study, where 6 years after diagnosis and initiation of treatment the mean HOMA-β index score were 28%. 45 Consistency of treatment effect regardless of β-cell function has also been observed previously for DPP-4 inhibitors. 46 A recent study has identified both C-peptide and islet autoantibodies as potential biomarkers that could allow patients with a good predicted response to GLP-1 RA therapy to be selected for treatment based on their β-cell function. 47 A limitation of this study is that there was no placebo comparator arm, as patient data were extracted from the single lixisenatide arms of 
